Comparative Study of Seropositive and Seronegative Arthritis in Adults
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.233 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Sanjay Ambhore und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
To compare the clinical features, laboratory findings, disease activity, radiological progression, and treatment response between seropositive and seronegative rheumatoid arthritis (RA) patients in adult populations. Materials and Methods: A retrospective comparative study was conducted on 259 adults diagnosed with rheumatoid arthritis (164 seropositive and 95 seronegative). Demographic data, clinical presentations, laboratory parameters including rheumatoid factor (RF) and anti-CCP antibodies, disease activity scores (DAS28-CRP), radiological findings, and therapeutic responses were systematically analyzed.
Results
Seropositive RA patients exhibited significantly higher disease activity at baseline (mean DAS28-CRP 5.8 ± 0.9 vs 5.2 ± 1.1, p < 0.001) and more frequent erosive joint involvement (72.6% vs 48.4%, p < 0.001). Treatment response at 3 months was better in seropositive patients (75.6% vs 52.6%, p < 0.001), but remission rates at 12 months were similar (68.3% vs 64.2%, p > 0.05). Radiographic progression showed comparable Sharp scores at 24 months between groups (p > 0.05). Extra-articular manifestations were significantly more common in seropositive patients (45.7% vs 22.1%, p < 0.001). Seronegative patients demonstrated slower initial treatment response but achieved comparable long-term outcomes with intensive therapy.
Conclusion
While seropositive RA presents with more aggressive initial disease activity and erosive changes, both groups achieve similar long-term remission rates when treated with intensive disease-modifying antirheumatic drugs (DMARDs). Serological status significantly influences early treatment response but does not predict long-term prognosis. Both seropositive and seronegative RA warrant aggressive treat-to-target strategies to optimize clinical outcomes and prevent radiological progression.
Zitieren
APA
Ambhore, S., Johri, S., & Jain, R. (2026). Comparative Study of Seropositive and Seronegative Arthritis in Adults. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.233
Vancouver
Ambhore S, Johri S, Jain R. Comparative Study of Seropositive and Seronegative Arthritis in Adults. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.233
BibTeX
@article{Ambhore2026,
author = {Ambhore, Sanjay and Johri, Sanjeev and Jain, Rohit},
title = {Comparative Study of Seropositive and Seronegative Arthritis in Adults},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.233}
}
EUVIMED